이톤 파마슈티컬스(ETON) 주가 전망 및 기업 분석 - PER·배당·실적·목표주가·RSI·MACD

ETON

Eton Pharmaceuticals Inc

7월 27일 4:00 PM ET (한국 7/28 05:00)

$42.31

-0.28 ▼ -0.66%

🌙 7월 27일 7:34 PM ET (한국 7/28 08:34)

$42.31

+0.00 +0.00%

이톤 파마슈티컬스(ETON) is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.

시가총액

$1.2B

스몰캡

P/E

배당수익률

없음

52주 위치

92%

저점 +207% · 고점 -6%

애널리스트

적극 매수

Fundamental health

vs. Drug Manufacturers - Specialty & Generic 소형주

수익성

Top 56%

성장

Top 17%

밸류에이션

Top 9%

재무 안정

Top 57%

Index ⓘ	RUT	P/E ⓘ	-	EPS (ttm) ⓘ	-0.07	Insider Own ⓘ	5.36%	Shs Outstand ⓘ	27.4M	Perf Week ⓘ	3.02%
Market Cap ⓘ	1.16B	Forward P/E ⓘ	20.91	EPS next Y ⓘ	135.97%	Insider Trans ⓘ	-22.45%	Shs Float ⓘ	25.9M	Perf Month ⓘ	21.51%
Enterprise Value ⓘ	1.17B	PEG ⓘ	0.2	EPS next Q ⓘ	0.16	Inst Own ⓘ	65.15%	Short Float ⓘ	4.73%	Perf Quarter ⓘ	83.8%
Income ⓘ	-0.00B	P/S ⓘ	13.33	EPS this Y ⓘ	145%	Inst Trans ⓘ	4.59%	Short Ratio ⓘ	2.74	Perf Half Y ⓘ	182.25%
Sales ⓘ	0.09B	P/B ⓘ	37.81	EPS next 5Y ⓘ	106.23%	ROA ⓘ	-1.62%	Short Interest ⓘ	1.23M	Perf YTD ⓘ	150.21%
Book/sh ⓘ	1.12	P/C ⓘ	58.95	EPS past 3/5Y ⓘ	21.89% 33.66%	ROE ⓘ	-5.36%	52W High ⓘ	-5.79% ($44.91)	Perf Year ⓘ	174.74%
Cash/sh ⓘ	0.72	P/FCF ⓘ	75.11	Sales past 3/5Y ⓘ	55.53% 359.57%	ROIC ⓘ	-2.95%	52W Low ⓘ	207.04% ($13.78)	Perf 3Y ⓘ	1455.51%
Dividend Est. ⓘ	-	EV/EBITDA ⓘ	181.2	EPS Y/Y TTM ⓘ	68.13%	Gross Margin ⓘ	54.77%	Volatility(W/M) ⓘ	5.09% 5.22%	Perf 5Y ⓘ	684.97%
Dividend TTM ⓘ	-	EV/Sales ⓘ	13.47	Sales Y/Y TTM ⓘ	79.89%	Oper. Margin ⓘ	2.65%	ATR (14) ⓘ	2.02	Perf 10Y ⓘ	-
Dividend Ex-Date ⓘ	-	Quick Ratio ⓘ	0.88	EPS Q/Q ⓘ	184.27%	Profit Margin ⓘ	-1.7%	RSI (14) ⓘ	64.87	Recom ⓘ	1
Dividend Gr. 3/5Y ⓘ	-	Current Ratio ⓘ	1.21	Sales Q/Q ⓘ	40.41%	SMA20 ⓘ	8.12% ($39.13)	Beta ⓘ	0.86	Target Price ⓘ	$46.7
Payout ⓘ	-	Debt/Eq ⓘ	1.02	Earnings ⓘ	2026/5/14	SMA50 ⓘ	22.03% ($34.67)	Rel Volume ⓘ	0.82	Prev Close ⓘ	$42.59
Employees ⓘ	44	LT Debt/Eq ⓘ	0.63	EPS/Sales Surpr. ⓘ	23.57% 8.76%	SMA200 ⓘ	83.2% ($23.09)	Avg Volume(3M) ⓘ	0.45M	Price ⓘ	$42.31
IPO ⓘ	2018/11/13	Option/Short ⓘ	Yes/Yes			Trades ⓘ	4872	Volume ⓘ	365,413	Change ⓘ	-0.66%

Quarterly earnings trend SEC filings · USD

24.6

24.9

24.12*

25.3

25.6

25.9

25.12*

26.3

Revenue Net income 최근 분기: 매출 $24M (YoY +40%) · 순이익 $2M (YoY +199%)

* Q4 figures are derived from the annual filing (10-K) · loss-making quarters are underlined in red

📊 Eton Pharmaceuticals Inc (ETON) Investment Analysis

What kind of company is Eton Pharmaceuticals Inc?

이톤 파마슈티컬스(ETON) 초고성장주

Healthcare · Drug Manufacturers - Specialty & Generic

Healthcare Stocks

💊 Eton Pharmaceuticals (ETON) is a US-based specialty pharmaceutical company focused on rare diseases. The company concentrates on directly commercializing treatments for ultra-rare diseases with small patient populations in the US, and holds a portfolio of multiple commercial products along with a late-stage development pipeline in the pediatric, metabolic, and endocrine areas.

Learn more about Eton Pharmaceuticals Inc →

Market Cap

$1.2B

Approx. KRW 1.6 trillion

⚖️ 0% of Samsung Electronics

Market Cap Rank2540

Employees44people

IPO2018/11/13

Current Price$42.31 ≈ 57,965원

📌 RUT · NASD · USA

Key Events

⏰ Upcoming events

🔔 Earnings release

The next release date has not been announced yet.

🎯 Ex-dividend date

No scheduled dividends

📜 Recent events

🔔 Earnings release 2026년 5월 14일 (목) · 장 마감 후 EPS +23.6% 매출 +8.8%

🔔 Earnings release 2026년 3월 19일 (목) · 장 마감 후 EPS -32.5% 매출 +3.4%

Is it profitable?

Profitability weak

Profitability — How efficiently it makes money

Operating Margin

Profit kept from selling products and services (higher is better)

2.6%

✓ 평균

My positionMid-range

Low range Average High range

Drug Manufacturers - Specialty & Generic 소형주 Median 8.8% · Bottom 42%

💡 일반적으로 10% 이상이면 양호, 20% 이상이면 우수

Net Margin

Share of revenue left after taxes and interest are paid

-1.7%

✓ 적자

💡 적자 상태 — 수익을 내지 못하고 있습니다

Gross Margin

Profit after subtracting raw-material costs only (signals product competitiveness)

54.8%

✓ 평균

My positionMid-range

Low range Average High range

Drug Manufacturers - Specialty & Generic 소형주 Median 57.7% · Bottom 46%

💡 제조업 30%, IT/소프트웨어 50% 이상이면 우수 (업종별 편차 큼)

ROE

Annual return earned on shareholders' equity (15%+ is strong)

-5.4%

✓ 적자

💡 적자 상태 — 수익을 내지 못하고 있습니다

ROA

Annual earnings relative to total company assets

-1.6%

✓ 적자

💡 적자 상태 — 수익을 내지 못하고 있습니다

ROIC

Return generated per dollar invested in the business

-3.0%

✓ 적자

💡 적자 상태 — 수익을 내지 못하고 있습니다

Financial health — Debt & liquidity burden

Debt-to-Equity (D/E)

Debt relative to equity (lower is healthier)

1.02

✓ Average

My positionMid-range

Low range Average High range

Drug Manufacturers - Specialty & Generic Median 0.36

💡 일반적으로 1.0 이하면 건전, 1.5까지는 무난 (금융·유틸·REIT는 구조적으로 높음)

Current Ratio

Liquid assets available to cover liabilities due within a year

1.21

✓ 평균

My positionMid-range

Low range Average High range

Drug Manufacturers - Specialty & Generic Median 2.47

💡 1.5~3.0 적정, 1.0 미만이면 단기 유동성 주의

Quick Ratio

Liquid assets excluding inventory, available for immediate use

0.88

✓ 평균

My positionMid-range

Low range Average High range

Drug Manufacturers - Specialty & Generic Median 1.68

💡 1.0 이상이면 안전, 0.5 미만이면 주의

* Ratings reflect relative position vs. peer-group distribution (same sector & size) plus absolute guards (loss & risk thresholds).

What's the outlook?

Positive Outlook

Price targets, growth, and valuation are favorable

애널리스트 목표가

$46.70

현재가 대비 +10.4%

💡 12개월 이내 도달을 전망하는 애널리스트 컨센서스 평균

예상 PER (Forward)

20.91배

💡 내년 예상 EPS 기준. 현재 PER과 비교해 이익 성장 반영 정도 확인

PEG (성장 반영 밸류)

0.20

저평가

💡 PEG < 1 — 성장 대비 저렴

내년 EPS 예상 성장률

+136.0%

💡 10% 이상이면 견조한 성장, 마이너스는 이익 감소 예상

5년 EPS 예상 연평균

+106.2%

💡 장기 성장 전망. 15% 이상이면 고성장 기업

⚠ 이 데이터는 애널리스트 추정치이며 실제 결과와 다를 수 있습니다. 투자 결정은 추가 검토와 함께 하세요.

Did earnings meet expectations?

High Earnings Volatility

Frequently misses analyst estimates

예상 상회

예상 부합

예상 하회

상회 비율

-2.5%

평균 서프라이즈

2026.05.14

부합

실적 $0.14 · 예상 $0.14 +0.0%

2026.03.19

하회

실적 $0.19 · 예상 $0.20 -5.0%

💡 예상보다 높은 실적을 자주 내는 기업은 실적 신뢰도가 높다고 평가됩니다. 단, 애널리스트 기대치가 낮게 설정되었을 수도 있으니 절대 수치도 함께 봐야 합니다.

Is it growing?

Strong Growth

Above the industry average, both historically and going forward

Healthy, Balanced Growth EPS and revenue are both growing steadily — a sustainable growth profile

🔮 How much will it grow? (analyst forecasts)

This Year's EPS Outlook

Projected EPS growth rate for this year

+145.0%

우수

My positionTop 25%

Low range Average High range

초고성장주 소형주 Median 51.6% · Top 19%

Next Year's EPS Outlook

Projected EPS growth rate for next year (analyst consensus)

+136.0%

우수

My positionTop 25%

Low range Average High range

초고성장주 소형주 Median 33.7% · Top 17%

5-Year EPS CAGR Outlook

Projected average annual EPS growth over the next 5 years

+106.2%

우수

My positionTop 5%

Low range Average High range

초고성장주 소형주 Median 40.0% · Top tier

📊 How much has it grown? (actual results)

Past 3-Year EPS

Actual average annual EPS growth over the past 3 years

+21.9%

양호

My positionMid-range

Low range Average High range

초고성장주 소형주 Median 6.9% · Top 34%

Past 5-Year EPS

Actual average annual EPS growth over the past 5 years

+33.7%

우수

My positionTop 25%

Low range Average High range

초고성장주 소형주 Median 7.0% · Top 21%

Past 5-Year Revenue

How much revenue grew over the past 5 years

+359.6%

우수

My positionTop 5%

Low range Average High range

초고성장주 소형주 Median 32.4% · Top tier

⚡ Short-term momentum

QoQ Revenue

Revenue change from the previous quarter (short-term momentum)

+40.4%

양호

My positionMid-range

Low range Average High range

초고성장주 소형주 Median 14.5% · Top 25%

* Forecast values are analyst consensus estimates. Ratings are determined by relative position vs. peer group of the same growth style and size.

New to investing terms? Look it up in the financial dictionary →

Has the stock risen over the long term?

Outperformed the market by 617%p over 5 years

ETON +685.0% · S&P 500 +68.4%

Excess return vs. market (price-based, ex-dividends)

5-year basis

vs S&P 500

+616.6%p

well ahead of the market

vs Health Care (XLV)

+660.5%p

well ahead of the sector average

1-year basis

vs S&P 500

+158.7%p

well ahead of the market

vs Health Care (XLV)

+155.0%p

well ahead of the sector average

Rank among peers

5-year return Top among peers Based on 25 peers

1-year return Top among peers Based on 28 peers

Current position within 52-week range

Low (-207.0%p) High (-5.8%p)

Current price is 207.0% above the 52-week low and 5.8% below the 52-week high

Recent risk (last 120 trading days)

Max drawdown

-21.7%

Annualized volatility

60.7%

Technical Indicators

Bollinger Bands · MACD · RSI · Stochastics · Ichimoku 5-line · recent 136-day series

Price · Bollinger Bands · Ichimoku Cloud

close
BB Upper
BB Mid
BB Lower
Tenkan
Kijun
Cloud (SpanA/B)

Bollinger Bands are upper and lower channels showing the closing price range (20 days · 2σ). Touching the upper band = overheated; touching the lower band = oversold. Ichimoku Cloud shows trend direction and strength through colored areas. Prices above the cloud indicate an uptrend; prices below indicate a downtrend. About Bollinger Bands →

🟢

Current diagnosis · 2026-07-27

Uptrend zone

Current price $42.31 above the midline ($39.13). Normal upward flow. Above the Ichimoku cloud (bullish).

MACD (12 · 26 · 9) Expand ▼

An indicator that uses the difference between the short-term EMA (12) and long-term EMA (26) to identify trend reversals. When MACD rises above the Signal line, it is a buy signal (golden cross); when it falls below, it is a sell signal (death cross). About MACD →

🟢

Current diagnosis · 2026-07-27

Bullish momentum holding

MACD 2.580 > Signal 2.319 in positive zone + Hist positive (+0.261). Trend in progress.

RSI(14) · Stochastics %K(14) Expand ▼

RSI measures short-term buying and selling pressure on a scale of 0–100. 30 or below = oversold (a rebound may be possible); 70 or above = overbought (a pullback may be possible). Stoch %K similarly measures short-term momentum strength. RSI · Learn more about Stochastics →

🟢

Current diagnosis · 2026-07-27

Bullish zone

RSI 64.9 (above the neutral level of 50). Buying pressure leads, supporting a steady rise. Stoch %K is also 73.8.

※ "Current diagnosis" is an automated interpretation based on standard thresholds and is for reference only. Make your own comprehensive judgment before trading.

Is it attractive at this price?

Pricier than peers in its industry

Pricey on Vs. Assets·Vs. Sales·Vs. Cash Flow, In line with peers on Vs. Earnings

💡 How to read this — Compare against peers in the same industry to see what the price is cheap or expensive relative to. Example: cheap vs. earnings = stock price is low relative to what the company earns; expensive vs. assets = stock price is high relative to assets on the balance sheet.

💵 Vs. Earnings Mid-range

🏢 Vs. Assets Pricey

🧾 Vs. Sales Pricey

💧 Vs. Cash Flow Pricey

💵 Vs. Earnings

Forward PER Forward Price-to-Earnings Ratio

PER using next year's estimated earnings — reflects growth

20.91x

✓ Fair

My positionMid-range

Low range Average High range

Drug Manufacturers - Specialty & Generic 소형주 median 10.48x · Around the industry average

💡 향후 12개월 예상 EPS 기준 PER. 현재 PER보다 낮으면 이익 성장 중

🏢 Vs. Assets

PBR Price-to-Book Ratio

Price vs. the company's asset value — below 1 trades cheaper than assets

37.81x

✓ Very pricey

My positionBottom 5%

Low range Average High range

Drug Manufacturers - Specialty & Generic 소형주 median 1.56x · Bottom 3% — expensive within the industry

💡 PBR 1 미만이면 청산가치 이하 (금융·제조업에서 특히 의미, IT는 낮은 비중)

🧾 Vs. Sales

PSR Price-to-Sales Ratio

Market cap vs. revenue — lower is cheaper relative to sales

13.33x

✓ Very pricey

My positionBottom 5%

Low range Average High range

Drug Manufacturers - Specialty & Generic 소형주 median 1.56x · Bottom 1% — expensive within the industry

💡 PSR 2 이하 저평가, 10 초과면 고평가 (고성장 기업일 때만 정당화)

💧 Vs. Cash Flow

EV/EBITDA Enterprise Value Multiple

Total enterprise value ÷ operating cash earnings — a benchmark for M&A

181.20x

✓ Very pricey

My positionBottom 5%

Low range Average High range

Drug Manufacturers - Specialty & Generic 소형주 median 9.45x · Bottom 1% — expensive within the industry

💡 EV/EBITDA 10 이하 저평가, 20 이상이면 고평가 (M&A 밸류 기준)

💧 Vs. Cash Flow

P/FCF Price-to-Free-Cash-Flow Ratio

Price vs. actual cash generation — lower means more efficient

75.11x

✓ Pricey

My positionBottom 25%

Low range Average High range

Drug Manufacturers - Specialty & Generic 소형주 median 9.25x · Bottom 13% — expensive within the industry

💡 P/FCF 20 이하면 현금창출 대비 저평가 (실질 수익성 기준)

Analyst target price (reference)

$46.70 vs. current price +10.4%

* Valuation is the stock's relative position within the industry peer group (same sector and market-cap range). Even when valuation looks attractive, check the 'Profitability' and 'Growth' sections too.

As of: Recent snapshot · Peer group: Drug Manufacturers - Specialty & Generic 소형주

Who owns it?

Ownership flow is positive

Insider net selling -22.4% · Institutional net buying +4.6% · Short interest light 4.7% · Short interest fell -5.0%p over the last 90 days

📈 Recent trading flow (6 months)

🧑‍💼 Insiders (executives & directors)

-22.4%

Insiders large net selling

🏦 Institutions (funds & investors)

+4.6%

Institutions net buying

💡 Net change over the past 6 months. Shows how much insiders and institutions increased or reduced their holdings, in %.

👥 Holdings composition

🏦 Institutions 65.2%

Adequate institutional weight

Healthcare 소형주 Median 65.6%

🧑‍💼 Insiders 5.4%

Meaningful insider stake

Healthcare 소형주 Median 17.6%

👤 Retail investors (estimated) 29.5%

Everyone excluding institutions and insiders

Institutions Insiders Retail (est.)

📉 Short-selling metrics

Short ratio

4.7%

Low — limited short-side pressure

Healthcare 소형주 Median 11.2%

Past 90 days 📉 -5.0%p decrease

Short interest days to cover

2.7 days

Days needed to close short positions using average trading volume

🧮 Share count

Total shares outstanding 27.4M주

Float (tradable shares) 25.9M주

* Insider/institutional flows are based on net changes over the past 6 months. Trend is cumulative over the past 90 days.

ETFs holding ETON

ETFs with the highest weightings · 10 total shown

IWC

iShares Micro-Cap ETF

0.13%

$1.4B

GSSC

Goldman Sachs ActiveBeta U.S. Small Cap Equity ETF

0.08%

$1.0B

QSML

WisdomTree U.S. SmallCap Quality Growth Fund

0.08%

$12M

IWO

iShares Russell 2000 Growth ETF

0.04%

$14.3B

OMFS

Invesco Russell 2000 Dynamic Multifactor ETF

0.03%

$281M

* Based on official quarterly filings. Latest disclosure; actual current weights may differ.

How much does it pay in dividends?

This company does not pay a dividend

It may be a growth-focused firm reinvesting profits into expansion. Consider this growth-stock profile when investing.

Compare Industry Peers

💡 vs. sector average ▲ Favorable / ▼ Unfavorable (Lower PER and PBR are better; higher ROE and dividend yield are better)

Sorted by market cap, largest first

Stock	Market Cap	PER	PBR	ROE	Dividend Yield	Change
ETON This Stock	$1.2B	-	37.8 ▼	-5.36% ▲	-	-0.7%
LLY	$1.13T	43.1 ▼	36.2 ▼	107.64% ▲	0.58% ▼	+0.1%
JNJ	$640.9B	30.8 ▼	7.5 ▼	25.74% ▲	2.02% ▲	+1.0%
ABBV	$453.9B	126.7 ▼	-	15221.82% ▲	2.67% ▲	-0.9%
UNH	$379.3B	26.9 ▼	3.9 ▼	12.49% ▲	2.16% ▲	-0.7%
MRK	$323.0B	36.8 ▼	7.0 ▼	18.97% ▲	2.5% ▲	-0.2%
Sector Avg	-	26.1	2.7	-48.83%	1.23%	-

FAQ

What kind of company is 이톤 파마슈티컬스(ETON)?

이톤 파마슈티컬스(ETON) belongs to the Healthcare sector and operates in the Drug Manufacturers - Specialty & Generic industry.

What is the market cap of ETON?

The market cap of ETON is approximately $1.2B, ranking 2,540 within its sector.

What is the 52-week high and low for ETON?

ETON has recorded a 52-week high of $44.91 and a low of $13.78.

면책조항: 본 콘텐츠는 참고 자료이며 투자 권유가 아닙니다. 모든 투자의 책임은 투자자 본인에게 있습니다.